PubMed

Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence.

Schlander M.

Child Adolesc Psychiatry Ment Health. 2007 Nov 15;1(1):13.PMID: 18005403 [PubMed - in process]Related articlesFree article

Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.

Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Muriel AC, Frank RG.

Arch Gen Psychiatry. 2005 Apr;62(4):435-41.PMID: 15809411 [PubMed - indexed for MEDLINE]Related articlesFree article

[The health economics of attention deficit hyperactivity disorder in Germany : Part 1: health care utilization and cost of illness.]

Schlander M, Trott GE, Schwarz O.

Nervenarzt. 2009 Nov 21. [Epub ahead of print] German. PMID: 19936696 [PubMed - as supplied by publisher]Related articles

[The prevalence of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany. Initial results from the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]

Schlack R, Hölling H, Kurth BM, Huss M.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 May-Jun;50(5-6):827-35. German. PMID: 17514469 [PubMed - indexed for MEDLINE]Related articles

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.PMID: 19445548 [PubMed - indexed for MEDLINE]Related articles

Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.

Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A.

Ann Pharmacother. 2008 Jan;42(1):24-31. Epub 2007 Nov 27.PMID: 18042808 [PubMed - indexed for MEDLINE]Related articles

Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.

Prasad S, Arellano J, Steer C, Libretto SE.

Int J Clin Pract. 2009 Jul;63(7):1031-40.PMID: 19570121 [PubMed - in process]Related articles

A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.

Hong J, Dilla T, Arellano J.

BMC Psychiatry. 2009 Apr 14;9:15.PMID: 19366449 [PubMed - indexed for MEDLINE]Related articlesFree article

The impact of diabetes and associated cardiometabolic risk factors on members: strategies for optimizing outcomes.

Hoerger TJ, Ahmann AJ.

J Manag Care Pharm. 2008 Feb;14(1 Suppl C):S2-14; quiz 15-6. Review.PMID: 18240890 [PubMed - indexed for MEDLINE]Related articlesFree article

How often are German children and adolescents diagnosed with ADHD? Prevalence based on the judgment of health care professionals: results of the German health and examination survey (KiGGS).

Huss M, Hölling H, Kurth BM, Schlack R.

Eur Child Adolesc Psychiatry. 2008 Dec;17 Suppl 1:52-8.PMID: 19132304 [PubMed - indexed for MEDLINE]Related articles

The economic impact of attention-deficit/hyperactivity disorder in children and adolescents.

Pelham WE, Foster EM, Robb JA.

Ambul Pediatr. 2007 Jan-Feb;7(1 Suppl):121-31. Review.PMID: 17261491 [PubMed - indexed for MEDLINE]Related articles

Children and adolescents with attention deficit-hyperactivity disorder: 1. Prevalence and cost of care.

Burd L, Klug MG, Coumbe MJ, Kerbeshian J.

J Child Neurol. 2003 Aug;18(8):555-61.PMID: 13677583 [PubMed - indexed for MEDLINE]Related articles

The economic impact of attention-deficit/hyperactivity disorder in children and adolescents.

Pelham WE, Foster EM, Robb JA.

J Pediatr Psychol. 2007 Jul;32(6):711-27. Epub 2007 Jun 7. Review.PMID: 17556402 [PubMed - indexed for MEDLINE]Related articles

Attention-deficit/hyperactivity disorder in children: excess costs before and after initial diagnosis and treatment cost differences by ethnicity.

Ray GT, Levine P, Croen LA, Bokhari FA, Hu TW, Habel LA.

Arch Pediatr Adolesc Med. 2006 Oct;160(10):1063-9.PMID: 17018466 [PubMed - indexed for MEDLINE]Related articlesFree article

Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Wigal SB.

CNS Drugs. 2009;23 Suppl 1:21-31. doi: 10.2165/00023210-200923000-00004. Review.PMID: 19621975 [PubMed - indexed for MEDLINE]Related articles

How often do children meet ICD-10/DSM-IV criteria of attention deficit-/hyperactivity disorder and hyperkinetic disorder? Parent-based prevalence rates in a national sample--results of the BELLA study.

Döpfner M, Breuer D, Wille N, Erhart M, Ravens-Sieberer U; BELLA study group.

Eur Child Adolesc Psychiatry. 2008 Dec;17 Suppl 1:59-70.PMID: 19132305 [PubMed - indexed for MEDLINE]Related articles

[Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]

Gaillez C, Sorbara F, Perrin E.

Encephale. 2007 Sep;33(4 Pt 1):621-8. French. PMID: 18033153 [PubMed - indexed for MEDLINE]Related articles

Pharmaceutical policies: effects of cap and co-payment on rational drug use.

Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, Kösters JP, Vernby A.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD007017. Review.PMID: 18254125 [PubMed - indexed for MEDLINE]Related articles

Who cares for patients with attention-deficit/hyperactivity disorder (ADHD)? Insights from Nordbaden (Germany) on administrative prevalence and physician involvement in health care provision.

Schlander M, Schwarz O, Trott GE, Viapiano M, Bonauer N.

Eur Child Adolesc Psychiatry. 2007 Oct;16(7):430-8.PMID: 17468967 [PubMed - indexed for MEDLINE]Related articles

A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.

Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS.

Value Health. 2008 May-Jun;11(3):376-88.PMID: 18489664 [PubMed - indexed for MEDLINE]Related articles